Cargando…
Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses
Nucleoside modified mRNA combined with Acuitas Therapeutics’ lipid nanoparticles (LNP) have been shown to support robust humoral immune responses in many preclinical animal vaccine studies and later in humans with the SARS-CoV-2 vaccination. We recently showed that this platform is highly inflammato...
Autores principales: | Ndeupen, Sonia, Bouteau, Aurélie, Herbst, Christopher, Qin, Zhen, Hutchins, Zachary, Kurup, Drishya, Diba, Leila Zabihi, Igyártó, Botond Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351776/ https://www.ncbi.nlm.nih.gov/pubmed/34373854 http://dx.doi.org/10.1101/2021.08.01.454662 |
Ejemplares similares
-
Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses
por: Ndeupen, Sonia, et al.
Publicado: (2022) -
The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021) -
The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021) -
Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion
por: Qin, Zhen, et al.
Publicado: (2022) -
Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion
por: Qin, Zhen, et al.
Publicado: (2022)